Drug Profile

PPMX T003

Alternative Names: PPMX-T003

Latest Information Update: 08 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Perseus Proteomics
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Transferrin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Large granular lymphocytic leukaemia
No development reported Haematological malignancies; Polycythaemia vera

Most Recent Events

03 Jul 2026 Perseus Proteomics has patent protection for PPMX T003 in Japan and China
03 Jul 2026 Perseus Proteomics receives notice allowance for PPMX T003 in USA
28 Jul 2025 No recent reports of development identified for phase-I development in Polycythaemia-vera in Japan (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com